Advagraf 5 mg prolonged-release hard capsules
Sponsors
Universitaetsklinikum Regensburg, Centre Hospitalier Universitaire De Limoges, Vall D'hebron Institut De Recerca, Vall D'hebron Institut De Recerca, Astellas Pharma Europe Limited, Stichting Amsterdam UMC
Conditions
Early graft dysfunction after heart transplantProphylaxis of primary liverProphylaxis of transplant rejection in adult kidney allograft recipientsProphylaxis of transplant rejection in adult liver allograft recipientsRenal transplantationand intestinal organ transplant rejectionheartkidney
Phase 2
A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow Up
CompletedCTIS2024-513546-11-00
Start: 2014-03-10End: 2025-11-03Target: 13Updated: 2025-06-12
Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure.
Not yet recruitingCTIS2024-516541-40-00
Target: 25Updated: 2026-01-07
Phase 4
Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients
Active, not recruitingCTIS2023-503531-18-00
Start: 2024-02-13Target: 300Updated: 2025-08-08
A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppression versus stopping immunosuppression at 6 months to safely prevent human leukocyte antigen (HLA) sensitization in patients with late renal graft failure
RecruitingCTIS2023-506879-98-00
Start: 2024-01-22Target: 202Updated: 2024-09-25
Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation
RecruitingCTIS2023-506601-19-00
Start: 2025-04-15Target: 200Updated: 2025-10-07
Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients
Active, not recruitingCTIS2024-518033-28-00
Start: 2020-11-27Target: 268Updated: 2025-12-03
Personalized Use of Resources Study (PURE)
CompletedCTIS2024-515542-16-03
End: 2025-01-28Target: 25Updated: 2025-01-17